Jones G H, Schneider C, Schneider H H, Seidler J, Cole B J, Stephens D N
Department of Neuropsychopharmacology, Schering AG, Berlin, Germany.
Psychopharmacology (Berl). 1994 Mar;114(2):191-9. doi: 10.1007/BF02244836.
This study compared the effects of the beta-carboline anxiolytic, abecarnil, with other benzodiazepine receptor (BZR) ligands, including the full agonists diazepam and alprazolam, and the partial agonists ZK 95962 and bretazenil (Ro 16-6028), and alpidem, in the mouse four-plate test and plus-maze. The efficacy and potency of each compound was related to the fraction of BZR occupied by the drug. Abecarnil was efficacious in both tests and showed anxiolytic effects comparable with alprazolam and diazepam. In the four-plate test, abecarnil, bretazenil, and ZK 95962 had selective effects on releasing exploratory locomotor activity suppressed by footshock (punished crossings). None of these compounds significantly altered non-punished crossings. In contrast, diazepam and alprazolam increased both unpunished and punished crossings at low to medium doses (receptor occupancies of approximately 20-60%). The number of punished and unpunished crossings fell to control levels or below at higher, more sedative doses (approximately 80% receptor occupancy). Alpidem had very weak anxiolytic-like effects in this test and markedly reduced unpunished crossings at relatively low receptor occupancies (> 15%). In the plus-maze, abecarnil increased the time spent in the open arms and the percentage open arm entries to an extent equal to that observed following diazepam or alprazolam administration. Bretazenil and ZK 95962 had weak effects on the measures of anxiolytic activity in this test. Alpidem also had little anxiolytic-like activity in the plus-maze but markedly reduced the total number of arm entries.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究在小鼠四板试验和十字迷宫试验中,比较了β-咔啉类抗焦虑药阿贝卡尼与其他苯二氮䓬受体(BZR)配体的作用,这些配体包括完全激动剂地西泮和阿普唑仑、部分激动剂ZK 95962和布瑞西坦(Ro 16-6028)以及阿吡坦。每种化合物的疗效和效价与药物占据BZR的比例有关。阿贝卡尼在两项试验中均有效,其抗焦虑作用与阿普唑仑和地西泮相当。在四板试验中,阿贝卡尼、布瑞西坦和ZK 95962对释放因足部电击而受抑制的探索性运动活动(受罚穿越)有选择性作用。这些化合物均未显著改变未受罚穿越次数。相比之下,地西泮和阿普唑仑在低至中等剂量(受体占有率约为20%-60%)时会增加未受罚和受罚穿越次数。在较高的、更具镇静作用的剂量(约80%受体占有率)下,受罚和未受罚穿越次数降至对照水平或更低。阿吡坦在该试验中的抗焦虑样作用非常微弱,在相对较低的受体占有率(>15%)时就显著减少了未受罚穿越次数。在十字迷宫试验中,阿贝卡尼增加了在开放臂停留的时间以及进入开放臂的百分比,其程度与给予地西泮或阿普唑仑后观察到的相当。布瑞西坦和ZK 95962在该试验中对抗焦虑活性指标的作用较弱。阿吡坦在十字迷宫试验中的抗焦虑样活性也很小,但显著减少了进入臂的总次数。(摘要截短至250字)